Trimethoprim-sulfamethoxazole induced prolonged hypoglycemia in an infant with MHC class II deficiency: diazoxide as a treatment option.

J Pediatr Endocrinol Metab 2003 Dec;16(9):1307-9

Division of Pediatric Endocrinology, Hacettepe University Faculty of Medicine, Ankara, Turkey.

Hyperinsulinemic hypoglycemia associated with trimethoprim-sulfamethoxazole (TMP-SMX) has generally been reported in adults who had renal impairment or in patients with AIDS using high dose TMP-SMX. We present a 5 month-old infant with immunodeficiency due to major histocompatibility complex class II expression defect, developing hypoglycemic convulsion on the third day of high dose TMP-SMX administration. High insulin and C-peptide levels were documented at the time of hypoglycemia. To overcome hypoglycemia while TMP-SMX tapered off, diazoxide was administered which resolved hypoglycemia in 2 months.

Download full-text PDF

Source
http://dx.doi.org/10.1515/jpem.2003.16.9.1307DOI Listing
December 2003
Get 20% Off Journals at LWW.com

Similar Publications

Disseminated Nocardiosis in a Renal Transplant Recipient.

Cureus 2021 Jan 5;13(1):e12497. Epub 2021 Jan 5.

Nephrology, Wayne State University School of Medicine, Detroit, USA.

Nocardiosis is an uncommon opportunistic Gram-positive bacterial infection caused by aerobic actinomycetes in the genus . can cause localized or systemic suppurative diseases involving eyes, kidneys, skin, lungs, bone, and central nervous system. Disseminated nocardiosis is a rare condition, seen among immunocompromised patients. Read More

View Article and Full-Text PDF
January 2021

[Early recurrence of pneumocystis pneumonia post trimethoprim-sulfamethoxazole therapy that developed after chemotherapy for follicular lymphoma].

Rinsho Ketsueki 2021 ;62(1):42-46

Division of Hematology, Department of Medicine, Keio University School of Medicine.

A 75-year-old man was treated with bendamustine-containing chemotherapy for follicular lymphoma. Trimethoprim-sulfamethoxazole (TMP-SMX) for pneumocystis pneumonia (PCP) prophylaxis was discontinued at the last course of the chemotherapy. However, the patient developed PCP 6 months after the last course, and treatment with TMP-SMX (480 mg/day) was initiated. Read More

View Article and Full-Text PDF
February 2021

Antimicrobial prophylaxis in patients with immune thrombocytopenia treated with rituximab: a retrospective multicenter analysis.

Ann Hematol 2021 Jan 26. Epub 2021 Jan 26.

Policlinico Paolo Giaccone, Unit of Haematology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, Palermo, Italy.

The primary aim of this study was to describe the use of primary anti-infective prophylaxis (AP) in common clinical practice in patients affected by immune thrombocytopenia (ITP) and treated with RTX. Population studied consisted of patients affected by ITP (age ≥ 18 years) who had received at least one dose of RTX from January 2008 to June 2018. Five Italian haematology centres participated in the current study. Read More

View Article and Full-Text PDF
January 2021

Adverse effects of trimethoprim-sulfamethoxazole for the prophylaxis of Pneumocystis pneumonia in dermatology.

J Dermatol 2021 Jan 25. Epub 2021 Jan 25.

Department of Dermatology, Shiga University of Medical Science, Otsu, Shiga, Japan.

Trimethoprim-sulfamethoxazole (TMP/SMX) combination is used for the prophylaxis of Pneumocystis pneumonia (PCP). Although TMP/SMX is frequently used in dermatology for cases treated with corticosteroids and/or immunosuppressants, it is often difficult to continue the administration of TMP/SMX due to adverse events. There are only a few reported studies on the prophylaxis of PCP in dermatology. Read More

View Article and Full-Text PDF
January 2021

High global consumption of potentially inappropriate fixed dose combination antibiotics: Analysis of data from 75 countries.

PLoS One 2021 20;16(1):e0241899. Epub 2021 Jan 20.

St George's, University of London, Paediatric Infectious Diseases Research Group, Institute of Infection and Immunity, London, United Kingdom.

Antibiotic fixed dose combinations (FDCs) can have clinical advantages such as improving effectiveness and adherence to therapy. However, high use of potentially inappropriate FDCs has been reported, with implications for antimicrobial resistance (AMR) and toxicity. We used a pharmaceutical database, IQVIA-Multinational Integrated Data Analysis System (IQVIA-MIDAS®), to estimate sales of antibiotic FDCs from 75 countries in 2015. Read More

View Article and Full-Text PDF
January 2021